ImmunityBio, Inc. — Director's Dealing 2025

Jun 21, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2025-06-18

Reporting Person: BLASZYK MICHAEL D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-18	Stock Option (right to buy)	$2.84	A	162786	Acquired	2035-06-18	Common Stock (162786)	Direct

Footnotes

F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.